Mitochondria-targeted half-sandwich iridium(<scp>iii</scp>)-Cp*-arylimidazophenanthroline complexes as antiproliferative and bioimaging agents against triple negative breast cancer cells MDA-MB-468
Ashaparna Mondal, Shanooja Shanavas, Utsav Sen, Utpal Das, Nilmadhab Roy, Bipasha Bose, Priyankar Paira
Abstract
phase cell-cycle arrest of MDA-MB-468 cells at the highest tested concentration of 5 μM. The study verdicts support the prospective therapeutic potential of the IrL1 complex in the treatment and eradication of triple negative breast cancer cells. These results validate that these types of scaffolds will be fairly able to exert great potential for tumor diagnosis as well as therapy in the near future.
Topics & Concepts
Triple-negative breast cancerIridiumChemistryCancer researchBreast cancerCancerBiologyBiochemistryGeneticsCatalysisMetal complexes synthesis and propertiesClick Chemistry and ApplicationsNanocluster Synthesis and Applications